On August 31, Ascendis Pharma A/S rose 5.92% in regular trading, trading at $262.27/share, with turnover of $34.16 million. The surge was driven by the announcement that Ascendis Pharma and BioMarin Pharmaceutical have signed a binding term sheet to resolve all global patent disputes concerning Yuviwel (Navepegritide), a therapy approved for treating linear growth failure in children with achondroplasia.

Under the agreement, Ascendis will pay royalties of 20% on US net sales and 18% on sales in the European Union, Brazil, and South Korea through May 2030. The license covers all present and future uses of the treatment, including achondroplasia. The deal terminates all pending legal proceedings in the US, Germany, Denmark, Brazil, and South Korea, and BioMarin will withdraw its International Trade Commission investigation. The resolution eliminates a significant legal overhang for Ascendis, securing commercial clarity for Yuviwel, which launched in the US earlier this year following FDA accelerated approval and a seven-year orphan drug exclusivity grant through February 2033.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)